Cairn Biosciences

About:

Cairn Biosciences is developing next-generation therapeutics that address significant challenges in the treatment of serious diseases.

Website: https://www.cairnbio.com/

Top Investors: National Science Foundation

Description:

Cairn Biosciences is developing next-generation therapeutics that address significant challenges in the treatment of serious diseases. Cairn’s drug discovery engine addresses the profound unmet need for new tools to decipher cellular complexity and enable scalable discovery of groundbreaking therapies. The company's proprietary approach enables us to monitor multiple dynamic facets of previously inaccessible biology in live cells and fast-track the discovery of a pipeline of drugs for a wide range of indications with an initial focus on cancer.

Total Funding Amount:

$1.06M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)cairnbio.com

Founders:

Mary Ludlam

Number of Employees:

1-10

Last Funding Date:

2016-08-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai